Metabolic Reprogramming in Nerve Cells

Metabolic Reprogramming in Mutant IDH1 Glioma Cells

BACKGROUND Mutations in isocitrate dehydrogenase (IDH) 1 have been reported in over 70% of low-grade gliomas and secondary glioblastomas. IDH1 is the enzyme that catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate while mutant IDH1 catalyzes the conversion of α-ketoglutarate into 2-hydroxyglutarate. These mutations are associated with the accumulation of 2-hydroxyglutarate ...

Metabolic Reprogramming in Arginine Deiminase-Resistant Cells

Authors’ Affiliations: Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida; Department of Neurology and Brain Science Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland *These authors contributed equally Corresponding Author: Macus T...

Dysregulated metabolic enzymes and metabolic reprogramming in cancer cells

Tumor cells carry various genetic and metabolic alterations, which directly contribute to their growth and malignancy. Links between metabolism and cancer are multifaceted. Metabolic reprogramming, such as enhanced aerobic glycolysis, mutations in the tricarboxylic acid (TCA) cycle metabolic enzymes, and dependence on lipid and glutamine metabolism are key characteristics of cancer cells. Under...

Metabolic reprogramming of myeloid-derived suppressive cells

Metabolic Reprogramming in Glioma

Many cancers have long been thought to primarily metabolize glucose for energy production-a phenomenon known as the Warburg Effect, after the classic studies of Otto Warburg in the early twentieth century. Yet cancer cells also utilize other substrates, such as amino acids and fatty acids, to produce raw materials for cellular maintenance and energetic currency to accomplish cellular tasks. The...